DOI: http://dx.doi.org/10.18203/2349-3933.ijam20211056

NT-pro brain natriuretic peptide in patients with type 2 diabetes mellitus without overt heart failure: a hospital based cross sectional study

Sanjay Varma, Archana Toppo, Khagdev Ram, Rajeev Lochan Khare, Yogendra Malhotra, Devpriya Lakra

Abstract


Background: Increased secretion of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) occurs mainly with increased tension in the ventricular walls, decreased oxygen supply, acute myocardial infarction, chronic cardiac heart failure, and in hypertrophy of the heart. Objective was to find out the prevalence and profile of NT-pro BNP levels in patients with type 2 diabetes mellitus (DM) without overt heart failure.

Methods: Hospital based cross sectional observational study was conducted in the Department of Medicine, Pt. JNM Medical College and associated Dr. BRAM Hospital Raipur, Chhattisgarh involving 106 patients of type 2 DM during the period of April 2019 to April 2020, after ethical approval from institutional ethical committee.

Results: The levels of NT pro BNP was found to be elevated in 87.7% patients of DM type 2. Majority of them were from 51-60 years age group (35.5%). Elevated NT proBNP levels was seen in 23.58% of patients having grade I diastolic dysfunction, 3.7% patients with grade II diastolic dysfunction and 1.88% patients having grade III diastolic dysfunction on echocardiography out of the 106 patients. Regardless of presence of diastolic dysfunction on echo, 93 (87.73%) patients out of the total study group of 106 patients had elevated BNP suggesting cardiac dysfunction. In the present study, 30.19% patients with diabetes were found to have varying degrees of diastolic dysfunction on echocardiography.

Conclusions: The prevalence of elevated NT pro BNP was 87.7%. Commonly observed age group with elevated NT pro BNP was 51-60 years. NT pro BNP was elevated in 88.7% of males and in 88.36% of females. Prevalence of elevated NT pro BNP was higher in grade 1 diastolic dysfunction with DM duration of more than 5 years (33.3%). Higher prevalence of elevated NT pro BNP was seen in grade I diastolic dysfunction (23.58%).

 


Keywords


NT-pro BNP, Type 2 diabetes mellitus, Echocardiography, Diastolic dysfunction

Full Text:

PDF

References


Hanseen KF, Bangstad HJ, BB rinchmann-Hansen O. Blood glucose control and diabetic microvascular complications: Long term effects of near normoglycemia. Diabet Med. 1992;9:697-705.

Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart study. Circulation. 2007;115:1544-50.

Zimmet P, Alberti KG, Shaw J. Global and societal implications of diabetes epidemic. Nature. 2001;414:782-7.

Alberti KG, Zimmet P, Shaw J. International diabetes federation: A consensus on Type 2 diabetes prevention. Diabet Med. 2007;24:451-63.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.

Steiner G. Diabetes and atherosclerosis: an overview. Diabetes. 1981;30:1-7.

Butler R, MacDonald TM, Struthers AD, Morris AD: The clinical implications of diabetic heart disease. Eur Heart J. 1998;19:1617-27.

Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol. 1992;70:3718.

Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Net- work (HyperGEN) study. Circulation. 2001;103:102-7.

Grossman E, Shemesh J, Shamiss A, Thaler M, Caroll J, Rosenthal T. Left Ventricular mass in diabetes-hypertension. Arch Intern Med. 1992;152:1001-4.

Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-41.

Tateyama H, Hino J, Minamino N, Kangawa K, Ogihara T, Matsuo H. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun. 1990;166:1080-7.

Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL, et al. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro : implications for assessment of left ventricular dysfunction. Clin Sci (Lond). 1999;258:255-8.

Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993;71:3-11.

Cheng V, Kazanegra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for peptide (BNP) predicts treatment outcomes in patients admitted for decompensated heart failure. J Am Coll Cardiol. 2001;37:386-91.

Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-74.

Castano Rodriguez S, Coma-Canella I, Lopez Salazar B, Barba Cosials J. Echocardiographic findings and NT-proBNP level in type-2 diabetic patients with and without ischemic heart disease. Revista Española de Cardiología (English Edition). 2009;62(10):1184-8.

Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004;27(8):1929-35.